Unity Biotechnology(UBX)
搜索文档
Unity Biotechnology(UBX) - 2022 Q2 - Earnings Call Presentation
2022-08-16 02:02
| --- | --- | --- | --- | --- | |-------------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | Corporate Overview Corporate Deck | | | | | | NASDAQ: UBX | | | | | | August 2022 | | | | | 2 Special Note Regarding Forward-looking Statements This presentation and the accompanying oral commentary contain forward-looking statements including statements related to UNITY's understanding of cellular senescence and the role it plays in diseases of aging, the potential f ...
Unity Biotechnology (UBX) Investor Presentation - Slideshow
2022-03-05 05:59
| --- | --- | --- | --- | --- | |-------------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | Corporate Overview Corporate Deck | | | | | | NASDAQ: UBX | | | | | | February 2022 | | | | | 2 Special Note Regarding Forward-looking Statements This presentation and the accompanying oral commentary contain forward-looking statements including statements related to UNITY's understanding of cellular senescence and the role it plays in diseases of aging, the potential ...
Unity Biotechnology (UBX) Investor Presentation - Slideshow
2021-03-16 05:06
BIOTECHNOLOG Y CORPORATE DECK March 2021 1 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 2 This presentation and the accompanying oral commentary contain forward-looking statements, including: statements regarding UNITY's understanding of cellular senescence and the role it plays in retinal and neurological diseases, the potential for UNITY to develop therapeutics to extend healthspan, including UBX1325 for retinal disease, expectations regarding the results of UNITY's clinical studies and UNITY's expec ...
Unity Biotechnology Inc (UBX) Investor Presentation - Slideshow
2020-09-16 02:53
BIOTECHNOLOG Y C O R P O R AT E D E C K September 2020 1 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 2 This presentation and the accompanying oral commentary contain forward-looking statements, including: the expected timing of date from the 24 week endpoints from Unity's Phase 2 clinical study and Phase 1b high-dose, repeat-dose clinical study of UBX0101, statements regarding UNITY's understanding of cellular senescence and the role it plays in osteoarthritis and retinal diseases, the potential for U ...
Unity Biotechnology (UBX) Investor Presentation - Slideshow
2020-03-20 01:40
CORPORATE 1 PRESENTATION March 2020 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS 2 This presentation and the accompanying oral commentary contain forward-looking statements, including: statements related to our understanding of cellular senescence and the role cellular senescence plays in diseases of aging; our ability to develop medicines that eliminate senescent cells; our expectations regarding the potential benefits, activity, effectiveness and safety of senolytic drug candidates; the status of our ...